Research and Development Investment: Sarepta Therapeutics, Inc. vs Verona Pharma plc

Biotech R&D: Sarepta vs. Verona's Decade of Investment

__timestampSarepta Therapeutics, Inc.Verona Pharma plc
Wednesday, January 1, 2014942310004101058
Thursday, January 1, 201514639400010763215
Friday, January 1, 20161882720005579049
Sunday, January 1, 201716670700032051299
Monday, January 1, 201840184300024482286
Tuesday, January 1, 201956090900043892589
Wednesday, January 1, 202072234300044505000
Friday, January 1, 202177118200079406000
Saturday, January 1, 202287709000049283000
Sunday, January 1, 202387738700017282730
Loading chart...

Igniting the spark of knowledge

A Decade of Innovation: R&D Investments in Biotech

In the competitive world of biotechnology, research and development (R&D) investments are crucial for innovation and growth. Over the past decade, Sarepta Therapeutics, Inc. and Verona Pharma plc have demonstrated contrasting strategies in their R&D expenditures.

Sarepta Therapeutics, a leader in genetic medicine, has consistently increased its R&D spending, peaking in 2023 with an investment nearly 10 times higher than its 2014 figures. This reflects a robust commitment to advancing therapies for rare diseases. In contrast, Verona Pharma, focusing on respiratory diseases, has shown a more modest growth in R&D spending, with a notable peak in 2021, marking a 93% increase from 2014.

These trends highlight the varying approaches within the biotech sector, where strategic R&D investments can significantly impact a company's innovation pipeline and market position.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025